Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate versus modafinil versus no treatment for excessive daytime sleepiness in drug-resistant epilepsy
IRCT20171030037093N22Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methylphenidate and modafinil in Excessive Daytime Sleepiness (EDS) (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Amount of drowsiness. Started Oct 2019; status: completed.
02
Drugs
methylphenidatemodafinil
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on IRCT20171030037093N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171030037093N22.